Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIGIL vs FOLFOXIRI in Metastatic Colorectal Cancer
NCT03222089Phase 2Withdrawn
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim, aldesleukin in metastatic colorectal cancer (mCRC), sponsored by Fujian Medical University Cancer Hospital. Planned start Jul 2017; status: withdrawn.
02
Drugs
sargramostimaldesleukin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03222089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222089.